^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Clear Cell Renal Cell Carcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Inlyta (axitinib) (VEGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASCO 2020
    Title:

    Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.

    Published date:
    05/13/2020
    Excerpt:
    In general, the pembro + axi benefit was observed in all subgroups tested, including IMDC risk and PD-L1 expression subgroups.
    DOI:
    10.1200/JCO.2020.38.15_suppl.5001
    Trial ID:
    KEYNOTE 426